Asterias Biotherapeutics Inc (AST) is Initiated by Chardan Capital Markets to Buy, Price Target at $5.50

Asterias Biotherapeutics Inc (AST) was Initiated by Chardan Capital Markets to “Buy” and the brokerage firm has set the Price Target at $5.50. Chardan Capital Markets advised their investors in a research report released on May 23, 2016.

Many Wall Street Analysts have commented on Asterias Biotherapeutics Inc. Rodman & Renshaw Initiated Asterias Biotherapeutics Inc on Apr 25, 2016 to “Buy”, Price Target of the shares are set at $12.

Asterias Biotherapeutics Inc closed down -0.03 points or -0.95% at $3.13 with 1,63,449 shares getting traded on Friday. Post opening the session at $3.2, the shares hit an intraday low of $3.1 and an intraday high of $3.36 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on May 17, 2016, Natale S Ricciardi (director) purchased 14,706 shares at $3.39 per share price. According to the SEC, on May 17, 2016, Don M Bailey (director) purchased 88,235 shares at $3.39 per share price. On May 17, 2016, Richard T. Lebuhn (director) purchased 15,000 shares at $3.39 per share price, according to the Form-4 filing with the securities and exchange commission.

Asterias Biotherapeutics Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Company’s product development is focused primarily on AST-OPC1 and AST-VAC2. The Company’s lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).

Asterias Biotherapeutics Inc

Leave a Reply

Asterias Biotherapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Asterias Biotherapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.